Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | 3.05% | |
| Calm After Storm | Range Contraction | 3.05% | |
| Lower Bollinger Band Walk | Weakness | 3.05% | |
| Outside Day | Range Expansion | 3.05% | |
| Wide Bands | Range Expansion | 3.05% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 19 hours ago |
| Up 5% | about 19 hours ago |
| Up 3% | about 19 hours ago |
| Up 2% | about 19 hours ago |
| Up 1% | about 19 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Cancer Treatment Therapeutic Products Blastoma Brain Tumor Cancer Center Glioma Metastases Neuroblastoma Diffuse Intrinsic Pontine Glioma Kettering Cancer Center Memorial Sloan Refractory
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Cancer Treatment Therapeutic Products Blastoma Brain Tumor Cancer Center Glioma Metastases Neuroblastoma Diffuse Intrinsic Pontine Glioma Kettering Cancer Center Memorial Sloan Refractory
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.9 |
| 52 Week Low | 4.6 |
| Average Volume | 357,560 |
| 200-Day Moving Average | 9.54 |
| 50-Day Moving Average | 15.20 |
| 20-Day Moving Average | 14.82 |
| 10-Day Moving Average | 14.38 |
| Average True Range | 1.13 |
| RSI (14) | 33.33 |
| ADX | 24.72 |
| +DI | 15.82 |
| -DI | 31.73 |
| Chandelier Exit (Long, 3 ATRs) | 14.38 |
| Chandelier Exit (Short, 3 ATRs) | 14.92 |
| Upper Bollinger Bands | 18.34 |
| Lower Bollinger Band | 11.31 |
| Percent B (%b) | 0.12 |
| BandWidth | 47.38 |
| MACD Line | -0.73 |
| MACD Signal Line | -0.25 |
| MACD Histogram | -0.4765 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.26 | ||||
| Resistance 3 (R3) | 13.33 | 13.04 | 13.08 | ||
| Resistance 2 (R2) | 13.04 | 12.76 | 13.01 | 13.02 | |
| Resistance 1 (R1) | 12.61 | 12.60 | 12.83 | 12.54 | 12.96 |
| Pivot Point | 12.32 | 12.32 | 12.43 | 12.29 | 12.32 |
| Support 1 (S1) | 11.89 | 12.04 | 12.11 | 11.82 | 11.40 |
| Support 2 (S2) | 11.60 | 11.88 | 11.57 | 11.34 | |
| Support 3 (S3) | 11.17 | 11.60 | 11.28 | ||
| Support 4 (S4) | 11.10 |
